SR7826 is a potent and selective small-molecule inhibitor of RIPK1 (receptor-interacting serine/threonine-protein kinase 1), a key mediator of necroptosis, inflammation, and immune signaling pathways. This specialty research chemical (≥98% purity) is primarily used in medical research to study autoimmune diseases and inflammatory conditions, including rheumatoid arthritis, lupus, and other immune-mediated disorders. By specifically targeting RIPK1, it serves as a valuable tool for dissecting disease mechanisms, evaluating therapeutic efficacy and safety in preclinical models, and exploring impacts on cellular processes to develop novel treatments for chronic inflammatory diseases.